Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters

Journal of Lipid Research

Volumn 52, Issue 11, 2011, Pages 1965-1973

  Castro Perez, Jose ^a,c   Briand, Franco̧is ^b   Gagen, Karen ^a   Wang, Sheng Ping ^a   Chen, Ying ^a   McLaren, David G ^a   Shah, Vinit ^a   Vreeken, Rob J ^c,d   Hankemeier, Thomas ^c,d   Sulpice, Thierry ^b   Roddy, Thomas P ^a   Hubbard, Brian K ^a   Johns, Douglas G ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Physiogenex   (France)

^c NETHERLANDS METABOLOMICS CENTRE   (Netherlands)

^d LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Cholesterol efflux; Cholesteryl ester transfer protein; High density lipoprotein; Low density lipoprotein

Indexed keywords

ANACETRAPIB; BILE ACID; CHOLESTEROL; CHOLESTEROL ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLIC ACID; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRITIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BILE FLOW; CHOLESTEROL EXCRETION; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; FECES; HAMSTER; LIVER; MACROPHAGE; MALE; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BIOLOGICAL TRANSPORT; CELL LINE; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; CRICETINAE; DYSLIPIDEMIAS; FECES; LIPOPROTEINS, HDL; MACROPHAGES; MALE; MICE; OXAZOLIDINONES;

EID: 80054094687     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M016410     Document Type: Article

References (41)

1. Gordon, T., W. P. Castelli, M. C. Hjortland, W. B. Kannel, and T. R. Dawber . 1977. High-density lipoprotein as a protective factor against coronary heart-disease-Framingham Study. Am. J. Med. 62 : 707-714. (Pubitemid 8110784)
2. Miller, N. E., D. S. Thelle, O. H. Forde, and O. D. Mjos . 1977. Tromso Heart-Study-high-density lipoprotein and coronary heartdisease - prospective case-control study. Lancet . 1: 965-968.
3. Keys, A. 1980. Alpha-lipoprotein (Hdl) cholesterol in the serum and the risk of coronary heart-disease and death. Lancet . 2 : 603-606. (Pubitemid 10056646)
4. Namboodiri, K. K., K. D. Bucher, E. B. Kaplan, P. M. Laskarzewski, C. J. Glueck, and B. M. Rifkind . 1985. A major gene for low-levels of high-density lipoprotein cholesterol-the Collaborative Lipid Research Clinics Family Study. Clin. Res. 33: A890.
5. Jacobs, D. R., I. L. Mebane, S. I. Bangdiwala, M. H. Criqui, and H. A. Tyroler. 1990. High-density lipoprotein cholesterol as a predictor of cardiovascular-disease mortality in men and women-the follow-up-study of the Lipid Research Clinics Prevalence Study. Am. J. Epidemiol. 131: 32-47.
6. Kitamura, A., H. Iso, Y. Naito, M. Iida, M. Konishi, A. R. Folsom, S. Sato, M. Kiyama, M. Nakamura, T. Sankai, et al. . 1994. High-densitylipoprotein cholesterol and premature coronary heart-disease in urban Japanese men. Circulation . 89: 2533-2539. (Pubitemid 24173667)
7. Davidson, M. H., J. M. McKenney, C. L. Shear, and J. H. Revkin. 2006. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. J. Am. Coll. Cardiol. 48 : 1774-1781. (Pubitemid 44648633)
8. McKenney, J. M., M. H. Davidson, C. L. Shear, and J. H. Revkin. 2006. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average highdensity lipoproteín cholesterol levels on a background of atorvastatin. J. Am. Coll. Cardiol. 48: 1782-1790. (Pubitemid 44648632)
9. Barter, P. J., M. Caulfi eld, M. Eriksson, S. M. Grundy, J. J. P. Kastelein, M. Komajda, J. Lopez-Sendon, L. Mosca, J. Tardif, D. D. Waters, et al. . 2007. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357: 2109-2122.
10. Forrest, M. J., D. Bloomfi eld, R. J. Briscoe, R. N. Brown, A. M. Cumiskey, J. Ehrhart, J. C. Hershey, W. J. Keller, X. Ma, H. E. McPherson, et al. . 2008. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br. J. Pharmacol. 154 : 1465-1473.
11. DePasquale, M., G. Cadelina, D. Knight, W. Loging, S. Winter, E. Blasi, D. Perry, and J. Keiser . 2009. Mechanistic studies of blood pressure in rats treated with a series of cholesteryl ester transfer protein inhibitors. Drug Dev. Res. 70: 35-48.
12. Hu, X., J. D. Dietz, C. S. Xia, D. R. Knight, W. T. Loging, A. H. Smith, H. D. Yuan, D. A. Perry, and J. Keiser . 2009. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition. Endocrinology . 150: 2211-2219.
13. Krishna, R., A. J. Bergman, B. Jin, M. Fallon, J. Cote, P. Van Hoydonck, T. Laethem, I. N. Gendrano 3rd, K. Van Dyck, D. Hilliard, et al. . 2008. Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Clin. Pharmacol. Ther. 84: 679-683.
14. Bloomfield, D., G. L. Carlson, A. Sapre, D. Tribble, J. M. McKenney, W. T. Littlejohn 3rd, C. M. Sisk, Y. Mitchel, and R. C. Pasternak. 2009. Effi cacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am. Heart J. 157: 352-360.
15. Cannon, C. P., A. Shah, H. M. Dansky, M. Davidson, E. A. Brinton, A. M. Gotto, M. Stepanavage, S. X. Liu, P. Gibbons, T. B. Ashraf, et al. . 2010. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N. Engl. J. Med. 363: 2406-2415.
16. Rader, D. J., E. T. Alexander, G. L. Weibel, J. Billheimer, and G. H. Rothblat . 2009. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J. Lipid Res. 50 : S189-S194.
17. Briand, F. 2010. The use of dyslipidemic hamsters to evaluate druginduced alterations in reverse cholesterol transport. Curr. Opin. Investig. Drugs . 11: 289-297.
18. Zhang, Y., I. Zanotti, M. P. Reilly, J. M. Glick, G. H. Rothblat, and D. J. Rader . 2003. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation . 108: 661-663. (Pubitemid 36999247)
19. Naik, S. U., X. Wang, J. S. Da Silva, M. Jaye, C. H. Macphee, M. P. Reilly, J. T. Billheimer, G. H. Rothblat, and D. J. Rader. 2006. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation . 113: 90-97. (Pubitemid 43958493)
20. Zhang, Y., J. R. Da Silva, M. Reilly, J. T. Billheimer, G. H. Rothblat, and D. J. Rader . 2005. Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo. J. Clin. Invest. 115: 2870-2874. (Pubitemid 41434414)
21. Moore, R. E., M. Navab, J. S. Millar, F. Zimetti, S. Hama, G. H. Rothblat, and D. J. Rader . 2005. Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased infl ammation. Circ. Res. 97: 763-771. (Pubitemid 41447126)
22. Briand, F., M. Treguier, A. Andre, D. Grillot, M. Issandou, K. Ouguerram, and T. Sulpice . 2010. Liver X receptor activation promotes macrophage-to-feces reverse cholesterol transport in a dyslipidemic hamster model. J. Lipid Res. 51: 763-770.
23. Fournier, N., O. Francone, G. Rothblat, D. Goudouneche, M. Cambillau, G. Kellner-Weibel, P. Robinet, L. Royer, N. Moatti, A. Simon, et al. . 2003. Enhanced effl ux of cholesterol from ABCA1-expressing macrophages to serum from type IV hypertriglyceridemic subjects. Atherosclerosis . 171: 287-293. (Pubitemid 37486081)
24. Mweva, S., J. L. Paul, M. Cambillau, D. Goudouneche, P. Beaune, A. Simon, and N. Fournier . 2006. Comparison of different cellular models measuring in vitro the whole human serum cholesterol effl ux capacity. Eur. J. Clin. Invest. 36: 552-559. (Pubitemid 44086770)
25. Bligh, E. G., and W. J. Dyer . 1959. A rapid method of total lipid extraction and purifi cation. Can. J. Biochem. Physiol. 37: 911-917.
26. Castro-Perez, J., S. F. Previs, D. G. McLaren, V. Shah, K. Herath, G. Bhat, D. G. Johns, S. P. Wang, L. Mitnaul, K. Jensen, et al. 2011. In vivo D 2 O labeling to quantify static and dynamic changes in cholesterol and cholesterol esters by high resolution LC/MS. J. Lipid Res. 52: 159-169.
27. Fahy E., S. Subramaniam, R.C. Murphy, M. Nishijima, C.R. Raetz, T. Shimizu, F. Spener, G. van Meer, M.J. Wakelam, and. E.A. Dennis. 2009. Update of the LIPID MAPS comprehensive classifi cation system for lipids. J Lipid Res 50 Suppl: S9-S14.
28. Cuchel, M., and D. J. Rader . 2006. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Circulation . 113 : 2548-2555. (Pubitemid 43948034)
29. Tchoua, U., W. D'Souza, N. Mukhamedova, D. Blum, E. Niesor, J. Mizrahi, C. Maugeais, and D. Sviridov . 2008. The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport. Cardiovasc. Res. 77: 732-739. (Pubitemid 351301865)
30. Niesor, E. J., C. Magg, N. Ogawa, H. Okamoto, E. von der Mark, H. Matile, G. Schmid, R. G. Clerc, E. Chaput, D. Blum-Kaelin, et al. 2010. Modulating cholesteryl ester transfer protein activity maintains effi cient pre-β-HDL formation and increases reverse cholesterol transport. J. Lipid Res. 51: 3443-3454.
31. Grove, D., and Pownall, H. J . 1991. Comparative specifi city of plasma lecithin:cholesterol acyltransferase from ten animal species. Lipids. 26: 416-420.
32. Liu, M., J. D. Bagdade, and P. V. Subbaiah . 1995. Specifi city of lecithin:cholesterol acyltransferase and atherogenic risk: comparative studies on the plasma composition and in vitro synthesis of cholesteryl esters in 14 vertebrate species. Lipid Res. 36: 1813-1824.
33. Matsuura, F., N. Wang, W. Chen, X. C. Jiang, and A. R. Tall. 2006. HDL from CETP-defi cient subjects shows enhanced ability to promote cholesterol effl ux from macrophages in an apoE- and ABCG1- dependent pathway. J. Clin. Invest. 116: 1435-1442.
34. Miwa, K., A. Inazu, M. Kawashiri, A. Nohara, T. Higashikata, J. Kobayashi, J. Koizumi, K. Nakajima, T. Nakano, M. Niimi, et al. 2009. Cholesterol effl ux from J774 macrophages and Fu5AH hepatoma cells to serum is preserved in CETP-defi cient patients. Clin. Chim. Acta . 402: 19-24.
35. Yvan-Charvet, L., J. Kling, T. Pagler, H. Li, B. Hubbard, T. Fisher, C. P. Sparrow, A. K. Taggart, and A. R. Tall . 2010. Cholesterol effl ux potential and antiinfl ammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler. Thromb. Vasc. Biol. 30: 1430-1438.
36. Evans, G. F., W. R. Bensch, L. D. Apelgren, D. Bailey, R. F. Kauffman, T. F. Bumol, and S. H. Zuckerman . 1994. Inhibition of cholesteryl ester transfer protein in normocholesterolemic and hypercholesterolemic hamsters: effects on HDL subspecies, quantity, and apolipoprotein distribution. J. Lipid Res. 35: 1634-1645. (Pubitemid 24291224)
37. van Heek, M., T. M. Austin, C. Farley, J. A. Cook, G. G. Tetzloff, and H. R. Davis . 2001. Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters. Diabetes . 50: 1330-1335. (Pubitemid 32500165)
38. Briand, F., S. U. Naik, I. Fuki, J. S. Millar, C. Macphee, M. Walker, J. Billheimer, G. Rothblat, and D. J. Rader . 2009. Both the peroxisome proliferator-activated receptor (PPAR) delta agonist GW0742, and ezetimibe promote reverse cholesterol transport in mice by reducing intestinal re-absorption of HDL-derived cholesterol. Clin. Transl. Sci. 2: 127-133.
39. Himber, J., B. Missano, M. Rudling, U. Hennes, and H. J. Kempen . 1995. Effects of stigmastanyl-phosphocholine (Ro 16- 6532) and lovastatin on lipid and lipoprotein levels and lipoprotein metabolism in the hamster on different diets. J. Lipid Res. 36 : 1567-1585.
40. Ugawa, T., H. Kakuta, H. Moritani, and H. Shikama . 2002. Experimental model of escape phenomenon in hamsters and the effectiveness of YM-53601 in the model. Br. J. Pharmacol. 135: 1572-1578. (Pubitemid 34270930)
41. Dong, B., M. Wu, H. Li, F. B. Kraemer, K. Adeli, N. G. Seidah, S. W. Park, and J. Liu . 2010. Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters. J. Lipid Res. 51: 1486-1495.